Why the study?
What is the prevalence and what are the risk factors for neuroleptic malignant syndrome in psychiatric inpatients exposed to neuroleptics?
What is the prevalence and what are the risk factors for neuroleptic malignant syndrome in psychiatric inpatients exposed to neuroleptics?
The prevalence of neuroleptic malignant syndrome in Chinese psychiatric inpatients is approximately 1.23 per 1,000, with depot fluphenazine decanoate being a notable risk factor, challenging previous assumptions about other risk factors.
Answers are grounded in this paper and cite their sources.
May warrant caution with depot fluphenazine in inpatients; leaves open causal confirmation and generalizability beyond this cohort.
In a prospective study of an estimated 9,792 inpatients treated with neuroleptic medication at a large Chinese psychiatric hospital, 12 patients developed neuroleptic malignant syndrome. The estimated prevalence of neuroleptic malignant syndrome in these psychiatric inpatients was 1.23/1,000 (95% confidence interval = 0.63/1,000 to 2.14/1,000). Unlike other investigators, the authors found that young adulthood, nonschizophrenic illness, oral high-potency neuroleptics, and concurrent use of lithium were not important risk factors for neuroleptic malignant syndrome. However, depot fluphenazine decanoate, particularly if used without an antiparkinsonian agent, was a risk factor.
No takes yet. Share an insight, caveat, or question.
Deng et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: